Author Archives: Deal With Cancer Team

KRAS-NRF2 in Cisplatin Resistance

Oncogenic KRAS mutations found in 20% to 30% of all non–small cell lung cancers (NSCLC) are associated with chemoresistance and poor prognosis. Here we demonstrate that activation of the cell protective stress response gene NRF2 by KRAS is responsib...

Bioengineered Model of Metastatic Cancer

Modeling the hematogenous spread of cancer cells to distant organs poses one of the greatest challenges in the study of human metastasis. Both tumor cell–intrinsic properties as well as interactions with reactive stromal cells contribute to this pro...